Arcutis Biotherapeutics
ARQT
115 hedge funds and large institutions have $1.05B invested in Arcutis Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 53 increasing their positions, 19 reducing their positions, and 12 closing their positions.
179% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 19
173% more call options, than puts
Call options by funds: $5.68M | Put options by funds: $2.08M
83% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 12
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
19% more capital inflows, than outflows
Capital inflows: $100M | Capital outflows: $84.4M
7% more funds holding
Funds holding: 107 → 115 (+8)
0.51% less ownership
Funds ownership: 95.96% → 95.44% (-0.51%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$18.9M |
| 2 |
GW&K Investment Management
Boston,
Massachusetts
|
+$9.5M |
| 3 |
Jennison Associates
New York
|
+$8.92M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.94M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$26.5M |
| 2 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$20.1M |
| 3 |
Logos Global Management
San Francisco,
California
|
-$10.3M |
| 4 |
Polar Capital Holdings
London,
United Kingdom
|
-$7.76M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$2.77M |
ARQT Hedge Fund Activity: Q2 2022 in Review
115 of the 5,964 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2022, worth a combined $1.05B — up 12% from $930M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ARQT positions and 12 closed out — a net gain of 10 holders — while 53 added to existing stakes and 19 trimmed.
The largest buyer was Pictet Asset Management (Switzerland), opening a new position worth an estimated $18.9M. The largest seller was OrbiMed, cutting an estimated $26.5M.
- 115 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2022, up from 107 in Q1 2022.
- Funds reported $1.05B of Arcutis Biotherapeutics stock for Q2 2022, up 12% quarter-over-quarter.
- 22 funds opened new Arcutis Biotherapeutics positions in Q2 2022 and 12 closed out, a net change of +10 holders.
- The largest Arcutis Biotherapeutics buyer in Q2 2022 was Pictet Asset Management (Switzerland), an estimated $18.9M added.
- The largest Arcutis Biotherapeutics seller in Q2 2022 was OrbiMed, an estimated $26.5M sold.
Based on aggregated 13F filings for Q2 2022.